FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1155-1156 October 26, 1995 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Dombret, H.

To the Editor: Dombret et al. (June 22 issue)¹ report a striking difference in the rates of complete response between patients treated with granulocyte colony-stimulating factor (G-CSF) after chemotherapy for acute myeloid leukemia (AML) and patients not given G-CSF. Although treatment with G-CSF shortened the duration of neutropenia, the mortality rate was not reduced during induction chemotherapy. Since the chemotherapy doses were equivalent, a direct antileukemic effect of G-CSF was postulated. This higher rate of complete response was translated into neither a longer period of complete response nor better event-free or overall survival. An unexpected and rather extraordinary antileukemic effect . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.